Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
19:44:16 EDT Mon 06 May 2024
Enter Symbol
or Name
USA
CA



News for U:MEDXF from 2023-05-07 to 2024-05-06 - 23 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-05-01 17:32U:MEDXFNews ReleaseMedexus Concludes Metoject Litigation, Patent No Longer in Effect in Canada
2024-04-02 07:32U:MEDXFNews ReleaseMedexus to Participate in the 2024 Bloom Burton & Co. Healthcare Investor Conference
2024-03-26 07:54U:MEDXFNews ReleaseFDA Approves Medexus's Supplemental Biologics License Application for IXINITY(R) to Treat Hemophilia B in Pediatric Patients
2024-02-07 17:59U:MEDXFNews ReleaseMedexus Announces Fiscal Q3 2024 Results
2024-01-30 07:01U:MEDXFNews ReleaseMedexus Schedules Third Fiscal Quarter 2024 Conference Call
2024-01-08 07:02U:MEDXFNews ReleaseHealth Canada Accepts for Review Medexus's New Drug Submission for Topical Terbinafine
2023-11-08 17:31U:MEDXFNews ReleaseMedexus Announces Strong Fiscal Q2 2024 Results, Including Quarterly Revenue of US$30.3 Million
2023-11-01 07:01U:MEDXFNews ReleaseMedexus Schedules Second Fiscal Quarter 2024 Conference Call
2023-09-21 17:01U:MEDXFNews ReleaseMedexus Holds Annual Meeting of Shareholders and Announces Election of Directors
2023-09-05 18:42U:MEDXFNews ReleaseMedexus Pharmaceuticals Announces C$10 Million Bought-Deal Public Offering of Units
2023-09-05 07:31U:MEDXFNews ReleaseMedexus Strengthens Balance Sheet with US$18 Million Commitment Under Accordion Facility
2023-08-17 17:31U:MEDXFNews ReleaseMedexus Study Supports Efficacy and Safety of IXINITY in Pediatric Patients with Severe or Moderately Severe Hemophilia B
2023-08-09 17:31U:MEDXFNews ReleaseMedexus Announces Strong Fiscal Q1 2024 Results, Including Record Quarterly Revenue of US$31.6 Million
2023-08-04 07:01U:MEDXFNews ReleaseMedexus to Participate in Fireside Chat at SHARE Series Event
2023-08-02 07:01U:MEDXFNews ReleaseMedexus Schedules First Fiscal Quarter 2024 Conference Call
2023-07-12 17:31U:MEDXFNews ReleaseMedexus Announces Preliminary Revenue for Fiscal Q1 2024
2023-06-21 17:41U:MEDXFNews ReleaseMedexus Generates Record Revenue of Us$108.1 Million in Fiscal Year 2023
2023-06-15 07:26U:MEDXFNews ReleaseFDA Accepts for Review Medexus's IXINITY Supplemental Biological License Application for Pediatric Patients
2023-06-14 17:31U:MEDXFNews ReleaseMedexus Schedules Fourth Fiscal Quarter and Fiscal Year 2023 Conference Call
2023-06-13 07:26U:MEDXFNews ReleaseMedexus Highlights Data on Trecondyv (Treosulfan) Presented at MDS 2023
2023-06-01 17:31U:MEDXFNews ReleaseMedexus to Participate in the LD Micro Invitational XIII
2023-05-10 17:31U:MEDXFNews ReleaseMedexus Announces Normal Course Issuer Bid, or NCIB, for Its Convertible Debentures
2023-05-09 18:22U:MEDXFNews ReleaseMedexus Demonstrates Cost-Effectiveness of Gleolan-Guided Surgery for High-Grade Glioma